Could the GSK share price and dividend be sunk by debt?

GlaxoSmithKline’s debt has risen from less than £2bn to over £25bn. Is it still a top dividend pick?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) is one of the five biggest companies in the FTSE 100 and pays generous dividends. As such, it’s long been a core holding in the portfolios of many investors.

However, its debt has increased dramatically over the last decade or two. Could this now pose a threat to its share price and dividend?

Ballooning debt

Back in the mid-2000s, GSK had net debt of less than £2bn. By the end of the decade this had risen to £9.4bn. Currently, it stands at £25.2bn.

Despite the ballooning debt, the company has continued to pay shareholders an 80p annual dividend since 2014. This payout amounts to nearly £4bn a year. Clearly, borrowing more and more money in order to maintain a dividend can’t continue indefinitely.

Prudent peers

In its annual results, released last week, GSK reported shareholders’ equity of £12m against the aforementioned net debt of £25.2m. This gives net gearing of 210% (net debt divided by shareholders’ equity multiplied by 100). Put another way, for every £1 of shareholders’ equity, GSK has £2.10 of debt.

This is very high compared with its global big pharma peers. Johnson & Johnson, Novartis, Roche, Pfizer and Sanofi all had net gearing of below 50% at their last reported year ends. I’d describe this as a prudent level of gearing. GSK hasn’t been in this club for over a decade.

Heading in the right direction

The good news for the Footsie firm’s shareholders is that while current net gearing of 210% is high, it’s come down from 491% at the end of 2018 when shareholders’ equity was £4.4bn against net debt of £21.6bn. The year before that (2017) shareholders’ equity was minus £68m against net debt of £13.2bn, meaning gearing was off the scale.

During these years, some analysts and investors feared the company would cut the dividend. Indeed, some urged it to do so. They argued GSK should allocate more capital to refreshing its pharmaceuticals pipeline.

However, management stuck to its guns. It was able to do this because lenders remained supportive. With net gearing now falling, and other ratios — such as net debt/EBITDA and interest cover — also heading in the right direction, GSK’s dividend looks more secure.

Buy, sell or hold?

I’m confident GSK’s business and balance sheet are on a stronger footing. But would I buy the stock today?

My Motley Fool colleague Michael Baxter described the company’s latest results as lacklustre. That’s a fair assessment, in my opinion. Earnings per share (EPS) of 123.9p came in slightly below a company-compiled consensus of 125p. Furthermore, for 2020, management has guided on a decline in EPS of between 1% and 4%.

On the face of it, this doesn’t seem particularly inspiring. However, I think the prospects for the business and the current valuation of the stock are attractive.

Management is increasing R&D investment in biopharma, and preparing its consumer healthcare business for a future demerger. I think its strategy has every prospect of creating significant value for buyers of the shares at a current price of 1,700p.

Trading at around 14 times forecast 2020 EPS of 119p-123p, and with the 80p dividend giving a yield of 4.7%, I rate the stock a ‘buy’.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Johnson & Johnson. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

This investment could offer both a second income and share price growth

Oliver says a second income can sometimes come at the cost of growth. But here's one company he thinks could…

Read more »

Investing Articles

Does the BP share price scream ‘value’ after its earnings report?

The BP share price might not scream 'value', but the stock represents a cheaper alternative to several peers in the…

Read more »

Bronze bull and bear figurines
Investing Articles

1 dividend giant I’d buy over Lloyds shares right now

I sold my Lloyds shares recently and have used some of the proceeds to buy more of this high-yielding FTSE…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£11,000 in savings? Here’s how I’d aim to turn that into a £19,119 annual passive income!

Investing a relatively small amount in high-yielding stocks and reinvesting the dividends paid can generate significant passive income over time.

Read more »

Investing Articles

Rolls Royce’s £4+ share price still looks a major bargain to me, so should I buy?

Rolls-Royce’s share price has shot up in the past year, but I think it’s still around 50% undervalued and is…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

A 10%+ yield but down 12%! Is this hidden FTSE 100 gem an unmissable passive income opportunity?

This FTSE 100 stock has one of the highest yields in the index, appears undervalued against its competitors, and looks…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

Here’s how much I’d need to invest in Greggs shares for £100 in monthly passive income

A dividend rising 11% a year, a resilient business model, and strong future prospects put Greggs among the best UK…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Should investors buy IAG right now with the share price near 179p?

Recent positive share price trends may continue with this week’s upcoming release of first-quarter figures for IAG.

Read more »